Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10899629 | Cancer Letters | 2014 | 7 Pages |
Abstract
The Cell Cycle Profiling - Risk Score (C2P-RS) based on CDK1 and CDK2 specific activities was significantly associated with relapse in breast cancers. We evaluated the prognostic value of the C2P-RS classification using a Japanese cohort including node-negative, hormone receptor-positive breast cancers treated with adjuvant endocrine therapy alone as systemic therapy. Of 266 patients, 22 (8.3%) relapsed within 5 years after surgery. The distribution of each C2P-RS group was 71.8% in the low group, 12.0% in the intermediate group, and 16.2% in the high group. The 5-year relapse-free survival rate in the low C2P-RS group (97.3%) was significantly higher than that in the intermediate C2P-RS group (84.3%) or the high C2P-RS group (74.4%) (Pâ<â0.001). The univariate analysis demonstrated that age, tumor size, histologic grade, and HER2 had no significant correlations with relapse but the C2P-RS classification (Pâ<â0.001) and Ki-67 (Pâ=â0.009) were significantly associated with relapse. Multivariate analysis showed only that the C2P-RS classification was a significant independent prognostic indicator. The C2P-RS classification might be a significant predictor of earlier recurrence in node-negative, hormone receptor-positive breast cancers treated with endocrine therapy.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Seung Jin Kim, Norikazu Masuda, Fumine Tsukamoto, Hideo Inaji, Futoshi Akiyama, Hiroshi Sonoo, Junichi Kurebayashi, Katsuhide Yoshidome, Masahiko Tsujimoto, Hiroyuki Takei, Shinobu Masuda, Seigo Nakamura, Shinzaburo Noguchi,